Biocon arm to acquire biosimilars business of Viatris for $3.34 bn
The Hindu
Kiran Mazumdar Shaw, executive chairperson of Biocon Biologics on Monday said BBL has entered into an agreement with Viatris to acquire its biosimilars business for $3.34 billion.
Bengaluru
Biocon subsidiary Biocon Biologics Ltd (BBL) has entered into a definitive agreement with its partner Viatris Inc to acquire Viatris’ biosimilars business for $3.34 billion.
Kiran Mazumdar Shaw, executive chairperson of Biocon Biologics on Monday said BBL has entered into an agreement with Viatris to acquire its biosimilars business for $3.34 billion, which would include cash of up to $2.34 billion and Compulsorily Convertible Preference Shares (CCPS) in BBL valued $1 billion.
“This acquisition is transformational and will create a unique fully integrated, global biosimilars enterprise. The deal will enable Biocon Biologics to attain a robust commercial engine in the developed markets of US & Europe and will fast-track our journey of building a strong global brand,’‘ she said.
Viatris would receive cash of $2 billion upon closing the deal and up to $335 million as additional payments in 2024. BBL would also issue CCPS worth $1 billion to Viatris.
The deal has been approved by the boards of both companies while the transaction is likely to be completed in the second half of 2022, as per BBL.
Viatris President Rajiv Malik would now serve on the board of Biocon, while Mazumdar-Shaw would continue as the Executive Chairperson of BBL.
Rupee hits all-time low at 85.20 against USD due to strong greenback, rising crude oil prices, and weak domestic markets.
Viatris faces U.S. FDA import alert for products from Indore plant, exceptions made for certain shortages.
xAI’s Grok may soon come to an iOS app as the company announced its Series C funding round of $6 billion.
Biocon and Zentiva receive EU approval for Liraglutide, a complex formulation for diabetes and weight management.
Equity markets fluctuate as Sensex and Nifty rise initially, then fall; global markets and oil prices also discussed.
Microsoft has been working on adding internal and third-party AI models to power Microsoft 365 Copilot.
China's dominance in critical minerals poses supply chain vulnerabilities for India, US, and EU nations, requiring strategic diversification efforts.
India's controversial popcorn tax system sparks outrage and criticism, with opposition questioning the complex GST rates.
ICAI President investigates auditing lapses at Byju's, disciplinary committee probing, details undisclosed, part of ongoing investigations.
Sensex and Nifty rebound sharply after steep decline, driven by value buying, bluechip stocks, and global market rally.
AS-IT-IS Nutrition aims for ₹300 crore GMV in 2025 with ATOM range, endorsed by Ravindra Jadeja.